Ultragenyx

Ultragenyx is a clinical-stage biopharmaceutical company founded in 2010, dedicated to developing novel therapeutics for rare and ultra-rare genetic diseases. The firm specializes in biologics and small-molecule treatments targeting metabolic disorders, bone diseases, and enzyme deficiencies. By leveraging innovative science, Ultragenyx addresses significant unmet medical needs for patients globally. Meet Ultragenyx's team to understand the leadership driving these clinical programs.

The company maintains a robust operational footprint with 6 global locations, supporting its research and commercialization efforts across North America, Europe, and Asia. With a workforce of 1,000-5,000 employees, the organization integrates advanced R&D with strategic pharmaceutical partnerships to accelerate drug development. Learn about Ultragenyx's global headquarters for detailed information regarding their operational infrastructure and geographic presence.

Trading under the ticker NASDAQ: RARE, Ultragenyx demonstrates a strong market position within the biotechnology sector. The company reported annual revenue of $717.0M, reflecting its ongoing commitment to commercial-stage growth and therapeutic innovation. Investors and stakeholders can Explore financial highlights to review detailed metrics, funding history, and fiscal performance. As a key player in the rare disease space, the firm continues to advance its pipeline through rigorous clinical-stage biotechnology initiatives and collaborative research efforts.